CELEX: 62020TA0715
Language: en
Date: 2022-03-02 00:00:00
Title: Case T-715/20: Judgment of the General Court of 2 March 2022 — Degode- v EUIPO — Leo Pharma (Skinovea) (EU trade mark — Opposition proceedings — Application for the EU word mark Skinovea — Earlier national word mark SKINOREN — Relative ground for refusal — Likelihood of confusion — Article 8(1)(b) of Regulation (EU) 2017/1001)

25.4.2022   
            
            
               EN
            
            
               Official Journal of the European Union
            
            
               C 171/28
            
         
      Judgment of the General Court of 2 March 2022 — Degode- v EUIPO — Leo Pharma (Skinovea)
      (Case T-715/20) (1)
      
      (EU trade mark - Opposition proceedings - Application for the EU word mark Skinovea - Earlier national word mark SKINOREN - Relative ground for refusal - Likelihood of confusion - Article 8(1)(b) of Regulation (EU) 2017/1001)
      (2022/C 171/36)
      Language of the case: English
      
         Parties
      
      
         Applicant: Degode-Dermago Development GmbH (Strausberg, Germany) (represented by: O. Spieker, A. Schönfleisch and N. Willich, lawyers)
      
         Defendant: European Union Intellectual Property Office (represented by: M. Capostagno and V. Ruzek, acting as Agents)
      
         Other party to the proceedings before the Board of Appeal of EUIPO: Leo Pharma A/S (Ballerup, Denmark)
      
         Re:
      
      Action brought against the decision of the Fifth Board of Appeal of EUIPO of 4 September 2020 (Case R 337/2020 5) relating to opposition proceedings between Leo Pharma and Degode-Dermago Development.
      
         Operative part of the judgment
      
      The Court:
      
                  1.
               
               
                  Dismisses the action;
               
            
                  2.
               
               
                  Orders Degode-Dermago Development GmbH to pay the costs.
               
            
         (1)  OJ C 35, 1.2.2021.